11606

509079

GUFICBIO

img img img img
No Data Available

Gufic Biosciences Share Price Update

As of the latest trading session, Gufic Biosciences share price is currently at ₹297.6, which is up by ₹18.64 from its previous closing. Today, the stock has fluctuated between ₹276.65 and ₹302.50. Over the past year, Gufic Biosciences has achieved a return of -13.99%. In the last month alone, the return has been -3.54%.

Gufic Biosciences performance

Today’s low

Today’s high

₹ 276.65 ₹ 302.50
₹ 293.85

52 week low

52 week high

₹ 268.00 ₹ 407.85
₹ 293.85

Open Price

₹ 280.90

Prev. Close

₹ 278.95

Volume (Shares)

154800.00

Total traded value

₹ 454.87

Upper Circuit

₹ 334.70

Lower Circuit

₹ 223.20

info

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Gufic Biosciences fundamentals


  • Market cap (Cr)

    2,946.80

  • P/E Ratio (TTM)

    56.14

  • Beta

    0.93

  • Book Value / share

    62.67

  • Return on equity

    12.33%

  • EPS (TTM)

    5.04

  • Dividend yield

    0.04%

  • Net profit/quarter (Cr)

    15.56

info icon alternate text
  • Market cap (Cr)

    2,958.30

  • P/E Ratio (TTM)

    56.14

  • Beta

    0.96

  • Book Value / share

    62.67

  • Return on equity

    12.33%

  • EPS (TTM)

    5.04

  • Dividend yield

    0.04%

  • Net profit/quarter (Cr)

    15.56

info icon alternate text

Gufic Biosciences Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2025 (Values in Cr)
Revenue 231.09
Operating Expense 210.83
Net Profit 15.56
Net Profit Margin (%) 6.73
Earnings Per Share (EPS) 1.55
EBITDA 37.10
Effective Tax Rate (%) 26.08
Particulars SEP 2025 (Values in Cr)
Revenue 230.42
Operating Expense 211.98
Net Profit 14.94
Net Profit Margin (%) 6.48
Earnings Per Share (EPS) 1.49
EBITDA 37.87
Effective Tax Rate (%) 27.22
Particulars JUN 2025 (Values in Cr)
Revenue 226.91
Operating Expense 211.53
Net Profit 12.07
Net Profit Margin (%) 5.31
Earnings Per Share (EPS) 1.20
EBITDA 33.23
Effective Tax Rate (%) 25.79
Particulars MAR 2025 (Values in Cr)
Revenue 205.02
Operating Expense 194.62
Net Profit 7.97
Net Profit Margin (%) 3.88
Earnings Per Share (EPS) 0.80
EBITDA 27.02
Effective Tax Rate (%) 26.06
Particulars DEC 2024 (Values in Cr)
Revenue 207.79
Operating Expense 183.38
Net Profit 19.32
Net Profit Margin (%) 9.29
Earnings Per Share (EPS) 1.93
EBITDA 35.81
Effective Tax Rate (%) 26.48
Particulars MAR 2025 (Values in Cr)
Revenue 819.81
Operating Expense 728.99
Net Profit 69.93
Net Profit Margin (%) 8.53
Earnings Per Share (EPS) 6.97
EBITDA 140.01
Effective Tax Rate (%) 25.93
Particulars MAR 2024 (Values in Cr)
Revenue 806.67
Operating Expense 693.17
Net Profit 86.14
Net Profit Margin (%) 10.67
Earnings Per Share (EPS) 8.74
EBITDA 148.05
Effective Tax Rate (%) 25.53
Particulars MAR 2023 (Values in Cr)
Revenue 690.62
Operating Expense 586.47
Net Profit 79.70
Net Profit Margin (%) 11.54
Earnings Per Share (EPS) 8.22
EBITDA 137.22
Effective Tax Rate (%) 25.31
Particulars MAR 2022 (Values in Cr)
Revenue 779.16
Operating Expense 655.43
Net Profit 95.84
Net Profit Margin (%) 12.30
Earnings Per Share (EPS) 9.89
EBITDA 151.14
Effective Tax Rate (%) 24.44
Particulars MAR 2021 (Values in Cr)
Revenue 487.70
Operating Expense 433.71
Net Profit 44.23
Net Profit Margin (%) 9.06
Earnings Per Share (EPS) 4.56
EBITDA 87.65
Effective Tax Rate (%) 23.35
Particulars MAR 2025 (Values in Cr)
Book Value / Share 59.93
ROE % 12.29
ROCE % 12.86
Total Debt to Total Equity 0.59
EBITDA Margin 17.04
Particulars MAR 2024 (Values in Cr)
Book Value / Share 53.11
ROE % 16.17
ROCE % 14.95
Total Debt to Total Equity 0.63
EBITDA Margin 18.53
Particulars MAR 2025 (Values in Cr)
Book Value / Share 59.96
ROE % 12.33
ROCE % 12.88
Total Debt to Total Equity 0.59
EBITDA Margin 17.08
Particulars MAR 2024 (Values in Cr)
Book Value / Share 53.11
ROE % 19.57
ROCE % 16.70
Total Debt to Total Equity 0.76
EBITDA Margin 18.53
Particulars MAR 2023 (Values in Cr)
Book Value / Share 35.88
ROE % 25.84
ROCE % 21.87
Total Debt to Total Equity 0.65
EBITDA Margin 19.87
Particulars MAR 2022 (Values in Cr)
Book Value / Share 27.76
ROE % 43.31
ROCE % 43.99
Total Debt to Total Equity 0.28
EBITDA Margin 19.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 17.89
ROE % 29.22
ROCE % 27.51
Total Debt to Total Equity 0.62
EBITDA Margin 17.97
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 29.02
Total Assets 1169.36
Total Liabilities 1169.36
Total Equity 601.07
Share Outstanding 10
Price to Book Ratio 5.61
Return on Assets (%) 5.95
Return on Capital (%) 7.64
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.48
Total Assets 1092.54
Total Liabilities 1092.54
Total Equity 532.56
Share Outstanding 10
Price to Book Ratio 5.33
Return on Assets (%) 7.88
Return on Capital (%) 10.14
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 28.20
Total Assets 1169.62
Total Liabilities 1169.62
Total Equity 601.36
Share Outstanding 10
Price to Book Ratio 5.61
Return on Assets (%) 5.97
Return on Capital (%) 7.67
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.47
Total Assets 1092.54
Total Liabilities 1092.54
Total Equity 532.56
Share Outstanding 10
Price to Book Ratio 5.33
Return on Assets (%) 7.88
Return on Capital (%) 10.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 46.68
Total Assets 861.15
Total Liabilities 861.15
Total Equity 347.80
Share Outstanding 9
Price to Book Ratio 5.20
Return on Assets (%) 9.25
Return on Capital (%) 12.09
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 26.57
Total Assets 521.40
Total Liabilities 521.40
Total Equity 269.11
Share Outstanding 9
Price to Book Ratio 8.97
Return on Assets (%) 18.38
Return on Capital (%) 29.01
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 13.17
Total Assets 392.06
Total Liabilities 392.06
Total Equity 173.43
Share Outstanding 9
Price to Book Ratio 6.39
Return on Assets (%) 11.28
Return on Capital (%) 19.33
Particulars MAR 2025 (Values in Cr)
Net Income 69.64
Cash from Operations 145.37
Cash from Investing -70.77
Cash from Financing -37.20
Net change in Cash 14.58
Free Cash Flow 145.37
Particulars MAR 2024 (Values in Cr)
Net Income 86.13
Cash from Operations 19.58
Cash from Investing -102.38
Cash from Financing 82.38
Net change in Cash -27.46
Free Cash Flow 19.58
Particulars MAR 2025 (Values in Cr)
Net Income 69.93
Cash from Operations 145.58
Cash from Investing -71.79
Cash from Financing -37.20
Net change in Cash 13.78
Free Cash Flow 145.58
Particulars MAR 2024 (Values in Cr)
Net Income 86.13
Cash from Operations 19.58
Cash from Investing -102.39
Cash from Financing 82.38
Net change in Cash -27.47
Free Cash Flow 19.58
Particulars MAR 2023 (Values in Cr)
Net Income 79.70
Cash from Operations 1.10
Cash from Investing -190.72
Cash from Financing 234.30
Net change in Cash 16.99
Free Cash Flow 1.10
Particulars MAR 2022 (Values in Cr)
Net Income 95.84
Cash from Operations 139.29
Cash from Investing -94.58
Cash from Financing -6.24
Net change in Cash 5.40
Free Cash Flow 139.29
Particulars MAR 2021 (Values in Cr)
Net Income 44.23
Cash from Operations 96.65
Cash from Investing -6.69
Cash from Financing -78.61
Net change in Cash 1.94
Free Cash Flow 109.05
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 28.41 12.30 1.47 217.72 23.12 42.00
BLISS GVS PHARMA LTD 201.65 19.28 1.88 2133.23 105.05 244.05
CIPLA LTD 1298.80 22.07 3.18 104914.55 1283.00 1672.20
FERMENTA BIOTECH LIMITED 339.00 11.28 2.55 997.71 241.30 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 28.41 27.32 3.96 217.72 23.12 42.00
AMRUTANJAN HEALTH CARE LTD. 528.05 26.40 4.46 1526.63 522.15 789.95
ASTRAZENECA PHARMA INDIA LTD. 8358.20 100.45 26.15 20895.50 6501.60 10653.05
BLISS GVS PHARMA LTD 201.65 27.47 1.93 2133.23 105.05 244.05

Gufic Biosciences shareholding pattern

Holding

23.31%
72.5%
0.44%
3.73%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

Gufic Biosciences Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
293.85 3.98 redarrow
red-green-graph indicator
6 Bearish
10 Bullish
  • 5 Days 284.90
  • 26 Days 290.40
  • 10 Days 284.60
  • 50 Days 301.20
  • 12 Days 285.00
  • 100 Days 317.60
  • 20 Days 287.70
  • 200 Days 335.20
282.38 PIVOT

First Support

277.67

First Resistance

287.32

Second Support

272.73

Second Resistance

292.03

Third Support

268.02

Third Resistance

296.97

RSI

41.64

ADX

38.53

MACD

-5.42

Williams % R

-54.45

Commodity Channel Index (CCI)

-23.94

Date

2026-03-16

Week

38632.00

Same Day

49114.00

Month

30037.00

1 Year

0.94

3 Year

0.77

Over 1 Month

-3.54%

down

Over 1 Year

-13.99%

down

Over 3 Months

-19.63%

down

Over 3 Years

12.57%

down

Over 6 Months

-22.25%

down

Over 5 Years

20.59%

down

Gufic Biosciences Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
22 Sep 2025 0.1 Final 22 Sep 2025 Equity shares
17 Sep 2024 0.1 Final 19 Sep 2024 Equity shares
21 Sep 2023 0.1 Final 21 Sep 2023 Equity shares
24 Aug 2022 0.1 Final 25 Aug 2022 Equity shares
09 Sep 2021 0.1 Final 14 Sep 2021 Equity shares
03 Nov 2020 0.05 Final 05 Nov 2020 Equity shares
20 Sep 2019 0.05 Final 24 Sep 2019 Equity shares
19 Sep 2018 0.05 Final 22 Sep 2018 Equity shares
28 Aug 2017 0.05 Final 30 Aug 2017 Equity shares
19 Sep 2016 0.05 Final 21 Sep 2016 Equity shares
22 Sep 2015 0.05 Final 24 Sep 2015 Equity shares
18 Sep 2014 0.05 Final 22 Sep 2014 Equity shares
02 Sep 2013 0.05 Final 23 Sep 2013 Equity shares
16 Aug 2012 0.05 Final 20 Aug 2012 Equity shares
16 Sep 2011 0.05 Final 20 Sep 2011 Equity shares
20 Sep 2010 0.05 Final 22 Sep 2010 Equity shares
17 Sep 2009 0.05 Final 19 Sep 2009 Equity shares
11 Dec 2008 0.05 Final 15 Dec 2008 Equity shares
19 Mar 2008 0.05 Final 25 Mar 2008 Equity shares
20 Sep 2006 0.0 Final 22 Sep 2006 Equity shares
22 Sep 2005 0.0 Final 24 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
04 Nov 2000 19 Oct 2000 5:2
04 Nov 2000 09 Oct 2000 5:2
Ex-Date Old FV NEW FV Record Date
29 Oct 2002 10.0 1.0 08 Nov 2002
Dividend date Dividend amount Dividend type Record date Instrument type
22 Sep 2025 0.1 Final 22 Sep 2025 Equity shares
17 Sep 2024 0.1 Final 19 Sep 2024 Equity shares
21 Sep 2023 0.1 Final 21 Sep 2023 Equity shares
24 Aug 2022 0.1 Final 25 Aug 2022 Equity shares
09 Sep 2021 0.1 Final 14 Sep 2021 Equity shares
03 Nov 2020 0.05 Final 05 Nov 2020 Equity shares
20 Sep 2019 0.05 Final 24 Sep 2019 Equity shares
19 Sep 2018 0.05 Final 22 Sep 2018 Equity shares
28 Aug 2017 0.05 Final 30 Aug 2017 Equity shares
19 Sep 2016 0.05 Final 21 Sep 2016 Equity shares
22 Sep 2015 0.05 Final 24 Sep 2015 Equity shares
18 Sep 2014 0.05 Final 22 Sep 2014 Equity shares
02 Sep 2013 0.05 Final 23 Sep 2013 Equity shares
16 Aug 2012 0.05 Final 20 Aug 2012 Equity shares
16 Sep 2011 0.05 Final 20 Sep 2011 Equity shares
20 Sep 2010 0.05 Final 22 Sep 2010 Equity shares
17 Sep 2009 0.05 Final 19 Sep 2009 Equity shares
11 Dec 2008 0.05 Final 15 Dec 2008 Equity shares
19 Mar 2008 0.05 Final 25 Mar 2008 Equity shares
20 Sep 2006 0.0 Final 22 Sep 2006 Equity shares
22 Sep 2005 0.0 Final 24 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
04 Nov 2000 19 Oct 2000 5:2
04 Nov 2000 09 Oct 2000 5:2
Ex-Date Old FV NEW FV Record Date
29 Oct 2002 10.0 1.0 08 Nov 2002

Top Gainers

Gufic Biosciences Share Price

Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients. Renowned for its extensive range of pharmaceutical products, Gufic operates as a comprehensive solution provider in both domestic and international markets, supported by a robust distribution network. The Company is ranked among the top 100 pharmaceutical companies in India.

Gufic is a leading manufacturer of lyophilized injections in India, with a state-of-the-art automated lyophilization plant located in Navsari, Gujarat. The Company was incorporated in July, 1984. The recent addition of the Indore manufacturing facility has further solidified Gufic's position as one of the world's largest producers of lyophilized injections. These products cover therapeutic areas, including antibiotics, antifungals, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs).

The Company made a reverse merger of itself with Central Finance. The promoters of GBL took over Central Finance at Rs 40-42 per share and then got GBL listed on BSE. Presently, the Company is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

The Choksi and Gandhi family, the promoters of GBL, have a long-standing presence in the pharma industry. In 1960, the family set up a joint venture company called Lyka Labs. In 1976, they decided to part ways and the Choksi family took over the manufacturing facility and the Gufic group of companies was born. Initially known as Gujarat Fine Chemicals, the first foray of the Gufic group was in the manufacture of various bulk drugs. The company later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products and bulk drugs that are sold in the domestic and the international markets.

Over the past several years, the company have a known reputation of creating brands that have vaulted to leadership positions in the category in which they have been marketed. To mention a few names: Shapers (sanitary napkins), Onergy, and Stretch nil.

In the year 2000, the company issued Bonus Equity Shares in proportion of five Equity shares for every two Equity shares held.

Gufic has divested brands in the ethical pharma business in a seller's market. The company plan to invest further in R&D activities and aggressively enter the herbal product and consumer product segments, where it foresee a huge potential. While benefiting from the rich, traditional knowledge base in India, it would like to operate from an area of strength in the herbal products segment.

In 2020-21, Gufic Lifesciences Private Limited amalgamated with the Company through the Scheme of Amalgamation which became effective from May 21, 2021. GUFIC UK LIMITED (GUL), a wholly owned subsidiary of the Company, was incorporated in United Kingdom on March 15, 2022. Similarly, in 2023, Gufic Ireland Limited (GIL) was incorporated on March 02, 2023.

Parent organization Indian Private
NSE symbol GUFICBIO
Founded 1984
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Gufic BioSciences Ltd?

Answer Field

Gufic BioSciences Ltd share price is for NSE ₹ 297.60 & for BSE ₹ 294.30 as on Mar 25 2026 03:29 PM.

What is the Market Cap of Gufic BioSciences Ltd Share?

Answer Field

The market cap of Gufic BioSciences Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Mar 25 2026 03:29 PM.

What is the 52 Week High and Low of Gufic BioSciences Ltd?

Answer Field

The 52 Week High and Low of Gufic BioSciences Ltd for NSE is ₹ 407.85 and ₹ 268.00 and for BSE is ₹ 409.00 and ₹ 268.65.

What is 1 year return for Gufic BioSciences Ltd?

Answer Field

The 1 year returns on the stock has been -13.99%.

What is the P/E Ratio of Gufic BioSciences Ltd Share?

Answer Field

As on Mar 25 2026 03:29 PM the price-to-earnings (PE) ratio for Gufic BioSciences Ltd share is 56.14.

What is the PB ratio of Gufic BioSciences Ltd Share?

Answer Field

As on Mar 25 2026 03:29 PM, the price-to-book (PB) ratio for Gufic BioSciences Ltd share is 62.67.

How to Buy Gufic BioSciences Ltd Share?

Answer Field

You can trade in Gufic BioSciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gufic BioSciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Gufic BioSciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gufic BioSciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59